Tropical disease vaccines

References

• Sutter RW, Tangermann RH, Aylward RB, Cochi SL. Poliomyelitis eradication: progress, challenges for the end game and preparation for the post-eradication era. Infect. Dis. Gun. N. Arn. 15(1), 41–64 (2001).
   Google Scholar
• Ashraf H. WHO takes another step towards polio eradication. Lancet 359(9325), 2255 (2002).
   PubMedGoogle Scholar
• Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am. J. Epidemic] 150(10), 1001–1021 (2001).
   Google Scholar
• Kew 0, Morris-Glasgow V, Landaverde M et al. Outbreak of poliomyelitis in Hispaniola associated with circulatingType 1 vaccine-derived poliovirus. Science 296(5566), 356–359 (2002).
   Google Scholar
• Vastag B. At polio's end game, strategies differ. JA/V/A 286(22), 2797–2799 (2001).
   Google Scholar
• Esparza J, Osmanov S, Pattou-Markovic C, Tour e C, Chang ML, Nixon S. Past present and future of HIV vaccine trials in developing countries. Vaccine20, 1897–1898 (2002).
   Google Scholar
• Nabel GJ. HIV vaccine strategies. Vaccine 20,1945–1947 (2002).
   PubMedGoogle Scholar
• Klein M. Current progress in the development of human immunodeficiency virus vaccines: research and clinical trials. Vaccine 19,2210–2215 (2001).
   PubMedGoogle Scholar
• Sattentau QJ, Moulard M, Brivet B et al Antibody neutralization of HIV-1 and the potential for vaccine design. Immunol Lett. 66,143–149 (1999).
   PubMedGoogle Scholar
• Edgeworth RL, San Juan H, Rozenzweig JA, Nguyen NL, Boyer JD, Ugen KE. Vaccine development against HIV-1: current perspectives and future directions. Immunologic. Res. 25(1), 53–74 (2002).
   Google Scholar
• Hanke T, McMichael A. Preclinical development of a multi-CTL epitope based DNA prime MVA boost vaccine for AIDS. Immunol Lett. 66,177–181 (1999).
   PubMed Web of Science ®Google Scholar
• Silvie 0, Danis M, Mazier D. Malaria-the disease and vaccine development. Vaccines Child Pract. 5,9-13 (2002).
   Google Scholar
• Egan JE, Hoffman SL, Haynes JD etal. Humoral immune responses in volunteers immunised with irradiated Plasmodium fair/pm-um sporozcoites. Am J. 7i-op. Med. Hyg. 49,166-173 (1993).
   Google Scholar
• Richie TL, Saul A. Progress and challenges for malaria vaccines. Nature 415,694 (2002).
   PubMed Web of Science ®Google Scholar
• Colditz GA, Brewer TF, Berkey CS et al Efficacy of BCG vaccine in the prevention of Tuberculosis. Meta analysis of the published literature. JA/VIA 271,698–702 (1994).
   Google Scholar
• International Union Against Tuberculosis and Lung Disease. Criteria for discontinuation of vaccination programmes using bacille Calmette Guerin (BCG) in countries with a low prevalence of tuberculosis. Tubeirle Lung Dis. 75,179–181 (1994).
   PubMedGoogle Scholar
• Orme IM, McMurray DN, Belisle JT. Tuberculosis vaccine development: recent progress. Trend Microbiol 9(3), 115–118 (2001).
   PubMed Web of Science ®Google Scholar
• Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of 4cobacterium tuberrulosis from the complete genome sequence. Nature 93,537–544 (1998).
   Google Scholar
• Collins HL, Kaufmann HE. Prospects for better tuberculosis vaccines. Lancet 1,21–28 (2001).
   Google Scholar
• Lindberg AA. Vaccination against enteric pathogens: from science to vaccine trials. CUIT: Opin. Mcrobiol. 1,16–124 (1998).
   Google Scholar
• Bresee JS, Glass RI, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 17,2207–2222 (1999).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Report of the meeting on future directions for rotavirus vaccine research in developing countries. Geneva, Switzerland, 9–11 February 2000. WHON&B/00.23.
   Google Scholar
• Ward RL, Bernstein DI. Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group..! Infect. Dis. 169(4), 900–904 (1994).
   Google Scholar
• MMWR. Intussusception among recipients of rotavirus vaccine — United States, 1998–1999. Morb. Mortal. Wkly Rep. 48(27), 577–581 (1999).
   Google Scholar
• Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. Infect. Dis. 168(2), 282–287 (1993).
   Google Scholar
• Ryan ET, Calderwood SB. Cholera vaccines. Travel Med. 8(2), 82–91 (2001).
   Google Scholar
• Clemens JD, Sack DA, Harris JR etal. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335(8684), 270–273 (1990).
   PubMed Web of Science ®Google Scholar
• Richie EE, Punjabi NH, Sidharta YY et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18(22), 2399–2410 (2000).
   Google Scholar
• Savarino SJ, Hall ER, Bassily S et al Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coil plus cholera toxin B subunit vaccine in Egyptian infants. Pediati: Infect. Dis. I 21(4), 322–330 (2002).
   Google Scholar
• Acharya IL, Lowe CU, Thapa R etal. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella Ophi. A preliminary report. N Engl. Med. 317(18), 1101-1104(1987).
   Google Scholar
• Typhoid vaccines. WHO position paper. Wkly Epidemiol Rec. 75,257–264 (2000).
   PubMedGoogle Scholar
• Coster TS, Hoge CW, VanDeVerg LL et al Vaccination against shigellosis with attenuated Shigella Ilexneri 2a strain 5C602. Infect. Immun. 67(7), 3437–3443 (1999).
   Google Scholar
• New strategies for accelerating Shigella vaccine development. WHO Wkly 431demiol. Rec. 72,73–80 (1997).
   Google Scholar
• Cohen D, Ashkenazi S, Green M et al. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect. Immun. 64(10), 4074–4077 (1996).
   PubMed Web of Science ®Google Scholar
• Ashkenazi S, Passwell JH, Harley E etal. Safety and immunogenicity of Shigella sonnel and Shigella flexneri 2a 0-specific polysaccharide conjugates in children. Infect. Dis. 179(6), 1565–1568 (1999).
   Google Scholar
• Wilde H. What are today's orphaned vaccines? Gila Infect. Dis. 33(5), 648–650 (2001).
   Google Scholar